$651 Million is the total value of Octagon Capital Advisors LP's 40 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 47.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $45,829,613 | -8.4% | 3,073,750 | -32.8% | 7.04% | +1.1% |
| VRNA | Sell | VERONA PHARMA PLCsponsored ads | $38,614,700 | -26.0% | 2,369,000 | -4.0% | 5.93% | -18.3% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $28,534,022 | +5.3% | 655,051 | -12.7% | 4.38% | +16.3% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $25,622,120 | +22.2% | 971,639 | -20.3% | 3.94% | +34.9% |
| RPHM | Sell | RENEO PHARMACEUTICALS INC | $17,361,210 | +11.7% | 2,279,870 | -3.7% | 2.67% | +23.4% |
| AVTE | Sell | AEROVATE THERAPEUTICS INC | $6,749,311 | -36.7% | 497,370 | -20.0% | 1.04% | -30.1% |
| Sell | XILIO THERAPEUTICS INC | $4,892,035 | -23.0% | 2,318,500 | -4.4% | 0.75% | -14.9% | |
| VIR | Sell | VIR BIOTECHNOLOGY INC | $3,045,719 | -80.9% | 325,050 | -50.0% | 0.47% | -78.9% |
| ORIC | Sell | ORIC PHARMACEUTICALS INC | $1,237,225 | -42.4% | 204,500 | -26.2% | 0.19% | -36.5% |
| ITOS | Sell | ITEOS THERAPEUTICS INC | $1,116,900 | -85.8% | 102,000 | -82.9% | 0.17% | -84.3% |
| Sell | HEPION PHARMACEUTICALS INC | $336,825 | -79.3% | 67,500 | -56.5% | 0.05% | -77.0% | |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -550,000 | -100.0% | -0.06% | – |
| PIRS | Exit | PIERIS PHARMACEUTICALS INC | $0 | – | -6,600,000 | -100.0% | -0.15% | – |
| VERA | Exit | VERA THERAPEUTICS INCcl a | $0 | – | -70,000 | -100.0% | -0.16% | – |
| ISEE | Exit | IVERIC BIO INCput | $0 | – | -50,000 | -100.0% | -0.27% | – |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -185,669 | -100.0% | -0.28% | – |
| Exit | STRUCTURE THERAPEUTICS INCsponsored ads | $0 | – | -75,000 | -100.0% | -0.43% | – | |
| GERN | Exit | GERON CORP | $0 | – | -2,278,000 | -100.0% | -1.02% | – |
| TVTX | Exit | TRAVERE THERAPEUTICS INC | $0 | – | -495,000 | -100.0% | -1.06% | – |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -474,929 | -100.0% | -1.62% | – |
| Exit | DISC MEDICINE INC | $0 | – | -415,000 | -100.0% | -2.56% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.